Synairgen Research Ltd.
Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection
- First Posted Date
- 2025-05-31
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Synairgen Research Ltd.
- Target Recruit Count
- 550
- Registration Number
- NCT06999603
Pilot Test of COVID-19 Related Clinical Outcome Assessment Methodology and Qualitative Evidence of Content Validity
- Conditions
- COVID-19
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- Synairgen Research Ltd.
- Target Recruit Count
- 29
- Registration Number
- NCT05207293
- Locations
- 🇺🇸
Henry Ford Health System, Detroit, Michigan, United States
🇬🇧University Hospitals Dorset NHS Foundation Trust, Bournemouth, Dorset, United Kingdom
🇬🇧Hull Royal Infirmary, Hull, East Riding Of Yorkshire, United Kingdom
Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2COVID-19
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-02-01
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- Synairgen Research Ltd.
- Target Recruit Count
- 623
- Registration Number
- NCT04732949
- Locations
- 🇺🇸
The University of Arizona Medi, Tucson, Arizona, United States
🇺🇸Professional Health Care of Pi, Saint Petersburg, Florida, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- Synairgen Research Ltd.
- Target Recruit Count
- 221
- Registration Number
- NCT04385095
- Locations
- 🇬🇧
Belfast City Hospital, Belfast, United Kingdom
🇬🇧Queen Elizabeth Hospital,, Birmingham, United Kingdom
🇬🇧Bradford Royal Infirmary, Bradford, United Kingdom
A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Other: Placebo
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- Synairgen Research Ltd.
- Target Recruit Count
- 122
- Registration Number
- NCT03570359
- Locations
- 🇬🇧
Celerion, Belfast, United Kingdom
🇬🇧Queen Elizabeth Hospital, Birmingham, United Kingdom
🇬🇧Bradford Royal Infirmary, Bradford, United Kingdom
- Prev
- 1
- 2
- Next